OP107
Anti-BRCA1 (Ab-4) Mouse mAb (SD118)
liquid, clone SD118, Calbiochem®
Sinónimos:
Anti-Breast Cancer Susceptibility Protein
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
NACRES:
NA.43
Productos recomendados
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
SD118, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... BRCA1(672)
General description
Anti-BRCA1 (Ab-4), mouse monoclonal, clone SD118, recognizes the ~220 kDa BRCA1 in HBL-100 and SK-BR3 cells. It is validated for WB, IF, IP, and for frozen sections.
Purified mouse monoclonal antibody generated by immunizing RBF/DnJ mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~220 kDa BRCA1 protein.
Recognizes the ~220 kDa BRCA1 protein in HBL-100 and SK-BR3 cells. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogen
Human
a recombinant polypeptide corresponding to amino acids 1005-1313 in exon 11 of human BRCA1
Application
Frozen Sections (2 µg/ml)
Immunoblotting (2 µg/ml, see application references)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg, see application references)
Paraffin Sections (not recommended)
Immunoblotting (2 µg/ml, see application references)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg, see application references)
Paraffin Sections (not recommended)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Analysis Note
Positive Control
HBL-100 or SK-BR3 cells
HBL-100 or SK-BR3 cells
Other Notes
Chen, J.J., et al. 1999. Cancer Res.59, 1752s.
Cressman, V.L., et al. 1999. Cell Growth Differ.10, 1.
Irminger-Finger, I., et al. 1999. Biol. Chem.380, 117.
Xu, X., et al. 1999. Nat. Genet.22, 37.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Fan, S., et al. 1998. Int. J. Cancer77, 600.
Gowen, L.C., et al. 1998. Science281, 1009.
Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA95, 12983.
Shen, S.X., et al. 1998. Oncogene17, 3115.
Tulchin, N., et al. 1998. Int. J. Oncol.13, 513.
Ludwig, T., et al. 1997. Genes Dev11, 1226.
Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA94, 7138.
Scully, R., et al. 1997. Cell90, 425.
Thakur, S., et al. 1997. Mol. Cell Biol.17, 444.
Wilson, C.A., et al. 1997. Oncogene14, 1.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol.23, 1.
Chen, Y., et al. 1996. Cancer Res.56, 3168.
Liu, C.Y., et al. 1996. Genes Dev.10, 1835.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Scully, R., et al. 1996. Science272, 123.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Wilson, C.A. et al. 1996. Nat. Genet.13, 264.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Miki, Y., et al. 1994. Science266, 66.
Cressman, V.L., et al. 1999. Cell Growth Differ.10, 1.
Irminger-Finger, I., et al. 1999. Biol. Chem.380, 117.
Xu, X., et al. 1999. Nat. Genet.22, 37.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Fan, S., et al. 1998. Int. J. Cancer77, 600.
Gowen, L.C., et al. 1998. Science281, 1009.
Hsu, L.C. and R.L. White. 1998. Proc. Natl. Acad. Sci. USA95, 12983.
Shen, S.X., et al. 1998. Oncogene17, 3115.
Tulchin, N., et al. 1998. Int. J. Oncol.13, 513.
Ludwig, T., et al. 1997. Genes Dev11, 1226.
Ruffner, H. and I.M. Verma. 1997. Proc. Natl. Acad. Sci. USA94, 7138.
Scully, R., et al. 1997. Cell90, 425.
Thakur, S., et al. 1997. Mol. Cell Biol.17, 444.
Wilson, C.A., et al. 1997. Oncogene14, 1.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin Oncol.23, 1.
Chen, Y., et al. 1996. Cancer Res.56, 3168.
Liu, C.Y., et al. 1996. Genes Dev.10, 1835.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Scully, R., et al. 1996. Science272, 123.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Wilson, C.A. et al. 1996. Nat. Genet.13, 264.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Miki, Y., et al. 1994. Science266, 66.
Maximal BRCA1 levels are observed in subconfluent cell populations after serum stimulation. Highly specific BRCA1 antibody useful for blotting and IP of full length BRCA1 protein. Antibody should be titrated for optimal results in individual systems.
Legal Information
Sold under license of U.S. Patents 5,753,441 and 6,162,897.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Herramienta de selección de productos.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Veronica Gomez Godinez et al.
PloS one, 15(4), e0227849-e0227849 (2020-04-29)
Understanding the mitotic DNA damage response (DDR) is critical to our comprehension of cancer, premature aging and developmental disorders which are marked by DNA repair deficiencies. In this study we use a micro-focused laser to induce DNA damage in selected
Maria C Villarroel et al.
Molecular cancer therapeutics, 10(1), 3-8 (2010-12-08)
Metastasis and drug resistance are the major causes of mortality in patients with pancreatic cancer. Once developed, the progression of pancreatic cancer metastasis is virtually unstoppable with current therapies. Here, we report the remarkable clinical outcome of a patient with
Myth T S Mok et al.
Traffic (Copenhagen, Denmark), 13(6), 800-814 (2012-03-17)
The breast cancer associated gene 1 (BRCA1)-A protein complex assembles at DNA damage-induced nuclear foci to facilitate repair of double-stranded breaks. Here, we describe the first systematic comparison of the dynamics, copy number and organization of its core components at
Amandine I Garcia et al.
EMBO molecular medicine, 3(5), 279-290 (2011-04-08)
Germ-line mutations in the BRCA1 gene strongly predispose women to breast cancer (lifetime risk up to 80%). Furthermore, the BRCA1 protein is absent or present at very low levels in about one third of sporadic breast cancers. However, the mechanisms
M Tanikawa et al.
British journal of cancer, 104(8), 1349-1355 (2011-03-17)
The TFII-I is a multifunctional transcriptional factor known to bind specifically to several DNA sequence elements and to mediate growth factor signalling. A microdeletion at the chromosomal location 7q11.23 encoding TFII-I and the related family of transcription factors may result
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico